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ligand, resulted in a reduction of cisplatin-induced DNA 
damage by 35% in cases, whereas in controls TGF-  had no 
effect. This reflects a statistically significant increase in cel-
lular chemoresistance to cisplatin following TGF-  stimula-
tion and helps to further understand effects of EGFR anti-
sense therapy in combination with chemotherapy. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Epidermal growth factor receptor (EGFR)-targeting 
therapeutics represent a major improvement in the treat-
ment of recurrent or metastatic squamous cell carcinoma 
in the head and neck (HNSCC). The rationale behind this 
is based on several findings:
 (a) the inhibition of EGFR signaling was shown to ef-
fectively decrease the proliferation rate using various
EGFR-overexpressing cell lines  [1] ;
 (b) HNSCC exhibits EGFR overexpression in up to 
90% of tumors  [2] ;
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 Abstract 
 The monoclonal epidermal growth factor receptor (EGFR) 
antibody cetuximab (Erbitux TM ) was recently approved by 
the European Medicines Agency for the treatment of recur-
rent and/or metastatic head and neck squamous cell carci-
noma (HNSCC) in combination with a platinum-based che-
motherapy. Since the antibody has only a limited effect as a 
monotherapy, possible explanations for the synergistic ef-
fect with cisplatin are enhanced antibody-dependent cytox-
icity and increased sensitivity to the drug. Most of our knowl-
edge of EGFR biology in HNSCC is based on studies using 
EGFR inhibitors and/or antibodies. Our study was designed 
to evaluate the impact of EGFR stimulation on cisplatin-in-
duced DNA damage. Therefore, tissue cultures were pro-
duced of tumor-free oropharyngeal mucosa biopsies of
HNSCC patients and controls. In a previous study, overex-
pression of EGFR in tissue cultures from tumor patients com-
pared to controls was confirmed by immunohistochemical 
staining. Twenty-four-hour stimulation of tissue cultures 
with transforming growth factor   (TGF-  ), a specific EGFR 
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 (c) somatic mutations of EGFR gene are frequently 
found in HNSCC  [3, 4] ;
 (d) EGFR expression level seems to be correlated with 
poor prognosis of cancer patients  [5] .
 While cetuximab (Erbitux TM ) has only limited efficacy 
as a monotherapeutic approach  [2, 5] , the monoclonal 
EGFR antibody was approved by the EMEA (European 
Medicines Agency 1 ) and FDA (Food and Drug Adminis-
tration, USA 2 ) for the treatment of locally advanced
HNSCC when combined with radiotherapy. Drugs tar-
geting EGFR intrinsic tyrosine kinase like erlotinib 
(Tarceva TM ) are currently under clinical investigation for 
the treatment of HNSCC.
 In this context, it is important to note that the develop-
ment of EGFR antisense therapeutics was widely based on 
observations made after EGFR inhibition. Cetuximab 
was shown to inhibit cell proliferation and decrease cell 
survival, to reduce cellular motility and tumor invasion 
and to diminish angiogenesis in various tumor models 
 [6–10] .
 EGFR activation, on the other hand, did not lead to 
consistent results. In a recent study, Song et al. [11] could 
show that EGF induces apoptosis in 3 carcinoma cell 
lines and that the ligand has more cytotoxic potential 
than EGFR blockers in these receptor-overexpressing 
cell lines. Studies showing that ligand-induced EGFR 
activation leads to apoptosis are reviewed by Danielsen 
and Maihle  [12] . As summarized by McCubrey et al. 
[13] , what they call ‘fine-tuning’ of the Raf/MEK/ERK 
signal transduction pathway, which lies downstream of 
EGFR activation, dictates whether there will be cell cy-
cle arrest or proliferation. In the future, further under-
standing of this ‘fine-tuning’ will help to develop more 
specific inhibitors of signal transducers like rapamycin 
 [14] .
 Recently, Vermorken et al. [15] reported the efficacy of 
cetuximab in combination with a platinum-based che-
motherapy as first-line treatment of recurrent or meta-
static HNSCC. Possible explanations for the synergistic 
effects include enhanced antibody-dependent cytotoxic-
ity and enhanced chemosensitivity  [16, 17] .
 It is an important feature of EGFR biology in HNSCC 
that the receptor is continuously activated by EGF-related 
growth factors produced by either the tumor cells them-
selves or surrounding stromal cells  [18] . Interestingly, in-
creased expression of EGFR and its specific ligand trans-
forming growth factor   (TGF-  ) was detected in histo-
logically normal mucosa of HNSCC patients compared 
to non-tumor patients  [19] .
 Our study evaluates the impact of TGF-  stimulation 
of human mucosal tissue cultures of tumor and control 
patients on cisplatin-induced DNA damage using the al-
kaline single-cell microgel electrophoresis (comet) assay.
 Materials and Methods 
 Mini-Organ Cultures 
 The study was approved by the ethics committee of Ludwig 
Maximilian University, Munich, Germany (project 349-05). All 
biopsy donors were informed by the investigators and signed an 
informed consent statement.
 We prepared mini-organ cultures (MOC) from fresh biopsied 
oropharyngeal mucosa samples from tumor and control patients. 
Samples were harvested during resection of oropharyngeal squa-
mous cell carcinomas and tonsillectomy, respectively. Biopsies of 
tumor patients were taken from macroscopically normal mucosa 
close to the tumor-free resection margins. In a previous study, 
EGFR overexpression of MOC from tumor patients was con-
firmed by immunohistochemical staining (data not shown).
 Specimens were dissected into cubes of 1 mm 3 excluding deep-
er layers and washed three times in bronchial epithelial cell basal 
medium (BEGM; supplemented with bovine pituitary extract, in-
sulin, hydrocortisone, epinephrine, triiodothyronine, transferrin 
and retinoic acid; Promocell, Heidelberg, Germany). Cubes were 
placed in 24-well plates, 1 each well, and coated with 0.75% Agar 
Noble (Difco, Detroit, Mich., USA) and dissolved in Dulbecco’s 
modified Eagle’s medium (Gibco, Eggenstein, Germany), 10% fe-
tal calf serum (Gibco), nonessential amino acids (Gibco) and am-
photericin B (Gibco). After about 20 days in 250   l BEGM, each 
well at 37.5   °   C, 5% CO 2 and 100% relative humidity, MOC were 
completely coated with epithelium. BEGM was replaced every 
second day during cultivation. Every seventh day, multiwell plates 
were changed to avoid adherence  [20] . As seen in  figure 1 , after 
complete epithelialization, the majority of cells within the MOC 
is of epithelial origin, and there is only a limited number of stro-
mal cells, vessels and glands. The model of MOC has several ad-
vantages compared to cell line experiments or animal models. In 
MOC, cells stay in their original surrounding tissue, which might 
have an impact on their metabolic competence  [21, 22] . Further-
more, standardized conditions can be applied. However, during 
the culturing process, additional oxidative stress and DNA dam-
age occurs  [23] .
 Cisplatin-Induced DNA Damage 
 Cisplatin is well known to produce interstrand cross-links 
within the DNA. Since the alkaline single-cell microgel electro-
phoresis assay is able to detect DNA strand breaks, hydrogen per-
oxide (H 2 O 2 ) was used to introduce random DNA fragmentation. 
Therefore, cisplatin-induced DNA cross-links reduced migration 
of DNA fragments compared to untreated DNA as measured with 
the comet assay  [24] .
 1   http://www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-
II-26-AR.pdf. December 19, 2008. 
 2   http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm095662.
htm. 
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 MOC were stimulated with TGF-  (100 ng/ml) dissolved in 
dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany) for
24 h. MOC were then washed twice before incubation with cis-
platin (10   M ; dissolved in DMSO) for another 24 h. This concen-
tration was previously shown to induce sufficient DNA cross-
links without inducing apoptosis in cell cultures  [24] . Thereafter, 
H 2 O 2 (1 m M ) induced random DNA fragmentation within 15 
min. MOC were finally washed again twice. All incubations were 
carried out at 37.5  °  C, 5% CO 2 and 100% relative humidity.
 Alkaline Single-Cell Microgel Electrophoresis (Comet) Assay 
 MOC were digested enzymatically thus gaining single cells.
As stated before, the majority of these cells are epithelial cells
 [20] . Enzyme suspension included collagenase P (Boehringer, 
Mannheim, Germany; 1 mg/ml), hyaluronidase (Boehringer;
1 mg/ml) and protease (Sigma; 5 mg/ml). MOC were suspended 
for 60 min at 37.5   °   C. After neutralizing histolytic enzymes with 
fetal calf serum (Gibco), single cells were washed twice in cold 
phosphate-buffered saline (Gibco), followed by trypan blue exclu-
sion test to monitor cell viability.
 Single cells were resuspended in 75   l 0.7% low-melting aga-
rose (FMC Bioproducts, Rockland, Me., USA) and the suspension 
was evenly distributed on slides between 2 layers of 85   l 0.5% 
normal-melting agarose (FMC Bioproducts). For better adhesion, 
slides had 5 mm frosted edges. Lysis of cellular and nuclear mem-
branes was performed under alkaline conditions in a solution 
containing 2.5  M NaCl (Sigma), 10 m M Trizma base (Merck), 100 
m M Na 2 EDTA (Serva, Heidelberg, Germany) and 1% N-lauroyl-
sarcosine sodium salt (Sigma) at pH 10, with 1% Triton X-100 (Sig-
ma) and 10% DMSO (Merck) added just before use. Subsequently, 
slides were positioned in a horizontal electrophoresis chamber 
(Renner, Dannstadt, Germany), close to the anode. Slides were 
covered with a 4  °  C cold alkaline buffer solution (pH 13.2) consist-
ing of 300 m M NaOH (Merck) and 1 m M Na 2 EDTA (Serva). 
 The DNA unwinded for 20 min before migration within an 
electric field (25 V, 1.0 V/cm, 300 mA, 20 min). Alkaline buffer 
was now neutralized with Trizma base solution (Merck; 400 m M , 
pH 7.5). Fluorescent DNA staining was performed with 75   l 
ethidium bromide (Sigma). After staining, slides were analyzed 
with a DMLB microscope (Leica, Bensheim, Germany). Eighty 
cell nuclei per slide were selected at random and digitized with the 
attached monochrome CCD camera (Cohu Inc., San Diego, Calif., 
USA). DNA migration was measured by the image analysis soft-
ware Komet++ (Kinetic Imaging, Liverpool, UK) using olive tail 
moments (OTM). OTM represents the multiplication of the rela-
tive amount of DNA in the tail with the median migration dis-
tance and is commonly used to measure comet assay results not 
giving any units.
 Statistical Analysis 
 Significant differences in DNA damage between the samples 
were calculated by the Friedman test using SPSS 16.0 software 
(SPSS GmbH, Munich, Germany). Calculation was based on the 
arithmetic mean of 80 OTM of each slide; the   level was set at 
0.05 prior to statistical analysis.
 Results 
 After all treatments, cell viability was  1 90% as as-
sessed by the trypan blue exclusion test.
 The solvent DMSO served as negative control and av-
erage OTM was 0.74 in controls and 0.86 in cases, reflect-
ing minor DNA damage occurring during the cultivation 
process  [25] . As expected, cisplatin did not lead to detect-
able DNA fragmentation using the alkaline version of the 
 Fig. 1. Histological slide of an MOC (con-
trol group; hematoxylin/eosin staining, 
 ! 500) showing the continuous epitheli-
um and the underlying connective tissue 
with small vessels and glands. 
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comet assay. OTM was 0.84, with and without prelimi-
nary stimulation with TGF-  in the non-tumor group. In 
cases, OTM was 0.77 without, and 0.76 after TGF-  stim-
ulation ( fig. 2 ).
 In controls, H 2 O 2 caused DNA damage with an aver-
age OTM of 9.7, which is statistically significant com-
pared to negative control (p  ! 0.001). Stimulation with 
TGF-  did not significantly change H 2 O 2 -induced DNA 
fragmentation, which is reflected by OTM 8.8. To evalu-
ate cisplatin-induced DNA cross-links, the introduction 
of random DNA strand breaks is necessary. Therefore, 
MOC were incubated with H 2 O 2 for 15 min. Lower OTM 
values then reflect higher levels of cisplatin-induced 
cross-links as linked DNA hardly dissociates during elec-
trophoresis  [24] . In controls, after prior incubation with 
cisplatin, average OTM due to H 2 O 2 -induced DNA frag-
mentation was 4.35. Compared to OTM 9.7 without
pretreatment with cisplatin, this shows significant
cross-linking levels (p  ! 0.001). In this group, previous 
stimulation of MOC with TGF-  for 24 h did
not significantly alter DNA cross-linking by cisplatin
(OTM = 4.23;  fig. 3 ).
 In cases, DNA damage caused by H 2 O 2 was not influ-
enced by TGF-  stimulation. OTM induced by H 2 O 2 sig-
nificantly decreased from 12.5 to 5.9 when MOC were 
previously treated with cisplatin due to cross-linking
(p  ! 0.001). Here, 24-hour stimulation with TGF-  before 
adding cisplatin significantly reduced DNA cross-links, 
which is reflected in increased OTM to 8 (p = 0.025; 
 fig. 4 ).
 Discussion 
 Our results show that TGF-  effectively reduces the 
ability of cisplatin to induce DNA cross-links. This effect 
could only be shown in MOC produced from macroscop-
ically normal oropharyngeal mucosa samples of tumor 
patients, whereas TGF-  had no impact on H 2 O 2 -in-
duced DNA fragmentation in controls. TGF-  had no ef-
fect on DNA damage induced by H 2 O 2 in either group.
 Cisplatin forms interstrand cross-link adducts on 
DNA, it interferes with DNA synthesis and activates cell 
death pathways  [26] . Therefore, possible explanations for 
our observation would be the reduction of cross-link for-
mation by reduced intracellular accumulation. Cisplatin 
enters the cell mostly by passive diffusion, although ac-
tive transportation might facilitate intracellular accumu-
OTM
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Non-tumor
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Non-tumor
TGF-
+ cisplatin
Tumor
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Tumor
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Tumor
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1.75 *
 Fig. 2. DNA damage (mean OTM) induced 
by the solvent DMSO and cisplatin with-
out/with prior stimulation of MOC with 
TGF-  for 24 h (n = 20, except tumor cis-
platin: n = 19; ° = extreme value;  * = out-
lier).  
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lation  [27] . Inside the cell, cisplatin is believed to react 
with a multitude of non-DNA targets, such as proteins 
and the cytoskeleton. The most important non-DNA tar-
get is glutathione  [28] . Cell line experiments showed in-
versely correlated intracellular glutathione levels and cis-
platin sensitivity  [29] . Furthermore, there seems to be a 
connection between extracellular ATP levels and cyto-
toxic effects of cisplatin  [30] .
 More recently, transporter proteins of the ABC family 
on the cellular surface were shown to confer drug resis-
tance  [31, 32] . There is growing evidence that cisplatin is 
a substrate of efflux pumps on the plasma membrane, ex-
truding the drug from the cell. This happens in two phas-
es. The so-called phase 0 ‘preemptive pumping’ describes 
the elimination of cisplatin before it can react with cel-
lular components immediately after entering the cell. The 
multidrug resistance protein 2 (cMoat) was shown to 
confer resistance to cisplatin  [33] and overexpression of 
multidrug resistance protein 2 has been described in at 
least 1 cisplatin-resistant cell line  [34] . In addition, after 
conjugation with glutathione, the complex is a substrate 
of the glutathione S-conjugate efflux pump  [35] during 
phase 3 metabolism.
 The exact mechanism of how TGF-  stimulation al-
tered cisplatin sensitivity in our study remains unclear. 
Since the growth factor had no influence on H 2 O 2 -in-
duced DNA fragmentation, major effects on cellular glu-
tathione levels are unlikely. In a previous study in our 
laboratory, MOC were incubated with benzo(a)pyrene 
diol epoxide, a well-established carcinogen, that – like 
cisplatin – forms DNA adducts. Benzo(a)pyrene diol ep-
oxide is likewise detoxified via conjugation with glutathi-
one. In this study, TGF-  did not affect DNA repair ca-
pacity  [36] .
 There is increasing evidence that EGFR downstream 
signaling pathways play a major role in the development 
of chemoresistance, even though experimental results are 
in part contradictory. While Garcia et al. [37] showed that 
stimulation of MCF-7 breast cancer cells with EGF (a spe-
cific EGFR ligand) induced the expression of genes in-
volved in drug resistance, Mandic et al. [38] found that 
cisplatin resistance of UT-SCC-26A head and neck can-
cer cells can be overcome after EGF stimulation. Using 
the same cell line, the latter group previously showed that 
EGFR inhibition by cetuximab significantly reduces cis-
platin IC 50  [39] .
 In contrast to most studies evaluating the influence of 
EGFR signaling in cisplatin resistance using cell lines and 
animal models, we used freshly biopsied tissue samples. 
Our results clearly show that simulation with TGF-  , a 
specific EGFR ligand  [40] , significantly reduces the abil-
ity of cisplatin to form DNA cross-links in MOC pro-
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*
 Fig. 3. DNA damage (mean OTM) caused by hydrogen peroxide 
and DNA cross-linking by cisplatin with/without prior stimula-
tion of MOC with TGF-  for 24 h in controls (n = 20; ° = extreme 
value). 
 Fig. 4. DNA damage (mean OTM) caused by hydrogen peroxide 
and DNA cross-linking by cisplatin with/without prior stimula-
tion of MOC with TGF-  for 24 h in cases (n = 20; ° = extreme 
value;  * = outlier). 
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